Bristol Myers Squibb BMY introduced that the FDA has authorized its CD19-directed chimeric antigen receptor (CAR) T cell remedy, Breyanzi (lisocabtagene maraleucel; liso-cel). www.nasdaq.com
Bristol Myers Squibb BMY introduced that the FDA has authorized its CD19-directed chimeric antigen receptor (CAR) T cell remedy, Breyanzi (lisocabtagene maraleucel; liso-cel).
www.nasdaq.com